U.S. Compounding Pharmacies Market (By Pharmacy Type: 503A, 503B; By Product: Oral, Liquid Preparations, Liquid Preparations, Rectal, Parenteral, Ophthalmic, Nasal, Otic; By Sterility: Sterile, Non-Sterile; By Compounding Type: PIA, CUPM, PDA, Others; By Application: Adult, Geriatric, Pediatric, Veterinary; By Therapeutic Area: Hormone replacement, Pain management, Dermatology, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022 – 2030


The U.S. compounding pharmacies market size was valued at US$ 3450.42 million in 2021 and is expected to surpass around US$ 5069.56 million by 2027 with a registered CAGR of 6.5% from 2020 to 2027.

U.S. Compounding Pharmacies Market Size 2020 to 2027

Growth Factors

The surging investments by the key market players in the research and development to innovate and customize the formulations to effectively treat various diseases are expected to boost the growth of the US compounding pharmacies market. The growing prevalence of cancer among the US population is significantly augmenting the market growth.

According to the National Cancer Institute, in 2020, approximately 1,806,590 new cancer cases were estimated to be diagnosed and about 606,520 cancer deaths were estimated in US. The most diagnosed type of cancer included breast cancer, lungs cancer, prostate cancer, and colon and rectum cancer. The lungs, prostate, and colorectal cancer collectively accounted for 43% of the total new cancer cases diagnosed in men, while in women, the breast, lungs, and colorectal cancer accounted for 50% in 2020. The cancer incidence or rate of new cancer cases in men is 442.4 per 100,000. The cancer death rate is 158.3 per 100,000 per year. It was estimated that around 16,850 adolescents and children aged 0 to 19 years would be diagnosed with cancer and around 1,730 would die out of it in 2020. US$150.8 billion was estimated to be the national cancer care expenditure in US in 2018.

Therefore, the surging cases of cancer in US are expected to significantly boost the growth of the US compounding pharmacies market in the forthcoming years. There has been a shortage of drugs owing to the longer lead times, lack of adequate raw materials, increased drug failure, and delayed production, which is a prominent factor behind the growth of the US compounding market. Furthermore, growing geriatric population base in US along with the better longevity is accelerating the market growth significantly. According to the Population Reference Bureau, by 2060, the geriatric population in US will constitute around 24% of the total US population.

The increasing acceptance of compounding pharmacies and the presence of favorable government policies pertaining to reimbursements is driving the growth of the US compounding pharmacies market. Further, the rising technological advancements is leading to the growth of the effective compounding pharmacies. The presence of leading market players coupled with the presence of strong healthcare infrastructure in US is augmenting the growth of the US compounding pharmacies market.

Report Scope of the U.S. Compounding Pharmacies Market

Report Coverage Details
Market Size by 2027 USD 5069.56 Million
Growth Rate from 2020 to 2027

CAGR of 6.5%

Non-sterile Segment Market Share in 2021 62.5%
Oral Medications Segment Market Share in 2021 51%
Base Year 2021
Forecast Period 2022 to 2030
Segments Covered Pharmacy Type, Product, Sterility, Application, Compounding Type, Therapeutic Area
Companies Mentioned Triangle compounding pharmacy, Fagron, B. Braun melsungen ag, Fresenius kabi ag, Pencol Compounding Pharmacy, US Compounding Inc., Avella specialty pharmacy, Institutional pharmacy solutions, llc, Pharmedium services llc, Vertisis custom pharmacy

 

Product Insights

Based on product, the oral medications segment dominated the US compounding pharmacies market, accounting for around 51% of the market share in 2021. The rising prevalence of various chronic diseases and increased preference for oral medications owing to its ease of use and easy storage has boosted the growth of this segment. The availability of various oral medications in the form of tablets, capsules, powder, and granules are some of the major and most preferred traditional form of oral medications. The increasing demand for the personalized medications among the various age groups is expected to foster the growth of the market in the upcoming years.

US Compounding Pharmacies Market Share, By Product, 2020 (%)

Parenteral segment accounted for around 18% of the US compounding pharmacies market share in 2021 and is expected to be the fastest growing segment during the forecast period. The ophthalmic care medicines like glaucoma are affordable and its higher acceptance among the patients is expected to drive its growth. The compounded dosage forms of glaucoma are increasingly adopted by the geriatric population in US. The compounding ophthalmic medications are also available in drops, tablets, capsules, and injection forms, which is a prominent factor behind its rising demand in US.

  • The oral medications segment was valued at US$ 1,194.89 million in 2020 and growth rate of this segment is projected to be 6.7% during the forecast period.
  • The topical medications segment was reached at US$ 994.27 million in 2020 and growth rate of this segment is projected to be 7% from 2020 to 2027.
  • The suppositories segment was estimated at US$ 358.24 million in 2020, growing at a projected CAGR of 5.7% over the forecast period.

Pharmacy Type Insights

Based on the pharmacy type, the 503A segment dominated the US compounding market in 2021. This segment is estimated to grow at a CAGR of 2.3% during the forecast period. The government restrictions on drug production and requirements of medicine prescriptions have led to the growth of the 503A segment in the market. It is highly used for domestic consumption and hence dominated the US market. The strict regulations for biannual monitoring and audit ensure the safety and quality of this product.

Sterility Insights

Depending on the sterility, the US compounding pharmacies market was dominated by the non-sterile segment that accounted for a market share of around 62.5% in 2021.

U.S. Compounding Pharmacies Market Share, By Sterility, 2021 (%)

The sterile segment is expected to witness the highest growth rate during the forecast period. The rising incidences of chronic ailments like cancer and cardiovascular diseases are expected to significantly drive the growth of the sterile segment in the upcoming future. The growing demand for the sterile compounding pharmacies owing to the increasing adoption of ophthalmic and parenteral medications is further fueling the growth of the segment during the forecast period.

Application Insights

On the basis of application, the adult segment was the dominating the market in 2021. This is attributed to the increased prevalence of various chronic ailments among the adult population in US. The increased healthcare spending and the increased adoption of health insurances among the adults have boosted the growth of this segment in the US compounding pharmacies market.

U.S. Compounding Pharmacies Market Share, By Application, 2021 (%)

The pediatric is estimated to be the most opportunistic segment during the forecast period. The growing preferences for customized compounded prescriptions and the development of flavored and sugar-free dosage forms by the pharmacists are expected to increase the demand for the compounding pharmacies among the children. The easy availability of the customized medications such as oral liquids, topical gels, gummy treats, and effervescent drinks is boosting the growth of the pediatric segment in US.

Therapeutic Area Insights

The pain medications segment was reached at US$ 1,109.24 million in 2020 and is projected to grow at a CAGR of 7.1% from 2020 to 2027. Pain is the most obvious symptom for which patients explore medical help. Acute pain can easily grow into chronic pain, which later becomes difficult to treat. Commercially convenient pain relief medications can treat chronic conditions such as arthritis, fibromyalgia, migraine, and other nerve and muscle pain; however, these medication can grow undesired side effects such as dizziness, drowsiness, or stomach irritation. Therefore, many patients seek a more suitable solution through pharmacy compounding.

US Compounding Pharmacies Market Share, By Therapeutic Area, 2020 (%)

Others include, oncology, haematology, dental, and others. Cancer patients are harder to live with than the disease itself. The adverse effects of chemotherapy can make patients weak and compromise their overall health, making other medications a complicated issue. Thus, oncology compounding is used by the doctor and prescribes a particular combination of drugs and treatments to meet patients' needs, minimizing the amount of time and effort a patient has to take medications. Innovative formulations such as mouthwash or topical creams are used to produce drugs who suffer from nausea, cannot swallow pills, or have other conditions that make traditional dosage difficult. Moreover, using topical medications decreases the effectiveness lost through absorption during the digestive process and the potential for adverse interaction with cancer treatment. Similarly, with dental compounding unpleasant experience and anxiety from patients can be removed, when dentist and pharmacist work together. Dental compounding has grown more popular in recent years because many variables go into a dental procedure. Dental compounding is the practice of developing customized medications for your dental needs. These customized medications are prescribed for procedural anxiety, pain relief, gum disease, mouth ulcers, and many others. Thus, the growing applications of others in compound pharmacies are likely to enhance market growth during the forecast period.

  • The hormone replacement therapies segment was valued at US$ 523.35 million in 2020 and is projected to grow at a CAGR of 6.7% over the forecast period.
  • The dermatological applications segment was estimated at US$ 925.56 million in 2020 and is expected to reach at a CAGR of 5.9%.

Key Market Developments

  • In May 2020, Wedgewood Pharmacy completed the acquisitions with Zoo, Wildlife specializations for acquisition of 503B outsourcing facilities and state licensed pharmacy. This strategy aimed at strengthening the market position on the company.
  • In November 2020, B Braun formed a strategic alliance with Grifols to integrate the B Braun’s Safe Infusion Systems with Grifols’ automated compounding portfolio for ensuring the safety of automated drug delivery.
  • In August 2021, Adamis Pharmaceuticals entered into a definitive agreement for selling a significant portion of assests of its subsidiary, US Compounding Inc.

The major players in the market are constantly involved in various developmental strategies such as partnerships, collaborations, agreement, mergers, and acquisitions to gain competitive advantage over others, strengthen their position in the market, and strengthen their product portfolio.

Some of the prominent players in the US compounding pharmacies market include:

  • Triangle compounding pharmacy
  • Fagron
  • B. Braun melsungen ag
  • Fresenius kabi ag
  • Pencol Compounding Pharmacy
  • US Compounding Inc.
  • Avella specialty pharmacy
  • Institutional pharmacy solutions, llc
  • Pharmedium services llc
  • Vertisis custom pharmacy

Segments Covered in the Report

(Note*: We offer report based on sub segments as well. Kindly, let us know if you are interested)

By Pharmacy Type

  • 503A
  • 503B

By Product

  • Oral
    • Capsules
    • Granules
    • Tablets
    • Powder
    • Others
  • Liquid Preparations
    • Emulsion
    • Syrup
    • Solutions
    • Suspension
    • Others
  • Topical
    • Gels
    • Ointments
    • Creams
    • Pastes
    • Others
  • Rectal
    • Enema
    • Suppositories
    • Others
  • Parenteral
    • SVP
    • LVP
  • Ophthalmic
  • Nasal
  • Otic

By Sterility

  • Sterile
  • Non-Sterile

By Application

  • Adult
  • Geriatric
  • Pediatric
  • Veterinary

By Compounding Type

  • Pharmaceutical Ingredient Alteration (PIA)
  • Currently Unavailable Pharmaceutical Manufacturing (CUPM)
  • Pharmaceutical Dosage Alteration (PDA)
  • Others

By Therapeutic Area

  • Hormone replacement
  • Pain management
  • Dermatology
  • Specialty drugs
  • Nutritional supplements
  • Others

Frequently Asked Questions

What is the current size of U.S. compounding pharmacies market?
The U.S. compounding pharmacies market size was reached at US$ 3450.42 million in 2021 and is anticipated to rake around US$ 5069.56 million by 2027.
The U.S. compounding pharmacies market is expected to grow at a CAGR of 6.5%. from 2020 to 2027.
The major players operating in the U.S. compounding pharmacies market are Triangle compounding pharmacy, Fagron, B. Braun melsungen ag, Fresenius kabi ag, Pencol Compounding Pharmacy, US Compounding Inc., Avella specialty pharmacy, Institutional pharmacy solutions, llc, Pharmedium services llc, and Vertisis custom pharmacy.
The surging investments by the key market players in the research and development to innovate and customize the formulations to effectively treat various diseases are expected to boost the growth of the US compounding pharmacies market.

PROCEED TO BUY

   USD 4500
   USD 7000
   USD 9000

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample